News Alnylam a ‘premier league’ addition to UK biotech UK base will be operational HQ, Switzerland to be official head office
News CRISPR Therapeutics plans Nasdaq launch CRISPR Therapeutics, the Swiss genome-editing company, has filed for a $90 million initial public offering.
News Amgen's Horizon buyout delivers Sjögren's disease win Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
